All In Biotech

Free tool

FAERS Monitor: Maxitrol

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 050023 or its brand name (Maxitrol, Dexamethasone, Neomycin Sulfate, Polymyxin B Sulfate). Reports on generic versions are filed under their own applications.

Reports

884

Serious

628

71% of reports

Hospitalization

223

Death reported

47

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • eye pain71
  • pain47
  • off label use45
  • headache44
  • vision blurred44
  • visual impairment41
  • eye irritation40
  • drug ineffective39
  • fatigue37
  • ocular hyperaemia37
  • dyspnoea35
  • anxiety34
  • intraocular pressure increased33
  • ulcerative keratitis32
  • dizziness31

Reports by year received

View as table
YearReports
20046
20052
20066
200714
20087
200912
201021
20115
201220
201330
201433
201542
201692
201738
201858
201967
202073
202148
202266
202378
202465
202558
202643

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,275 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
ulcerative keratitisSignal32281.2199.78,557
intraocular pressure increasedSignal3361.644.11,903
eye painSignal7130.024.01,963
ocular hyperaemiaSignal3718.613.5598
eye irritationSignal4016.512.2570
visual impairmentSignal417.95.8241
vision blurredSignal447.65.7248
anxietySignal342.82.039
pain471.81.417
headache441.71.312
dizziness311.51.04
dyspnoea351.51.15
off label use451.20.92
fatigue371.10.80
drug ineffective390.70.55

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.